Programmed death-ligand 1 (PD-L1) expression is higher in TNBC than in other breast cancers, providing the rational for recently approved immunotherapy with anti-PD-L1 antibodies, in combination with PTX, for advanced PD-L1-positive TNBC [91]. Here, CD274 is linked to breast cancer.